Michael Hershfield

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
    Nancy J Ganson
    Division of Rheumatology, Box 3049, Duke University Medical Center, Durham, NC 27710, USA
    Arthritis Res Ther 8:R12. 2006
  2. ncbi request reprint New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency
    Michael S Hershfield
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Eur J Immunol 35:25-30. 2005
  3. pmc Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo
    Michael S Hershfield
    Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:14351-6. 2010
  4. ncbi request reprint Genotype is an important determinant of phenotype in adenosine deaminase deficiency
    Michael S Hershfield
    Box 3049, Rom 418 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Immunol 15:571-7. 2003
  5. pmc Reassessing serum urate targets in the management of refractory gout: can you go too low?
    Michael S Hershfield
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Rheumatol 21:138-42. 2009
  6. ncbi request reprint Uricase and other novel agents for the management of patients with treatment-failure gout
    John S Sundy
    Duke University Medical Center, Durham, NC 27710, USA
    Curr Rheumatol Rep 9:258-64. 2007
  7. ncbi request reprint Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV
    Eva Richard
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biol Chem 277:19720-6. 2002
  8. ncbi request reprint Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
    John S Sundy
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Arthritis Rheum 56:1021-8. 2007
  9. ncbi request reprint Purine nucleoside phosphorylase deficiency (PNP-def) presenting with lymphopenia and developmental delay: successful correction with umbilical cord blood transplantation
    Laurie A Myers
    Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr 145:710-2. 2004
  10. ncbi request reprint Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells
    Mario Gonzalez-Gronow
    Department of Pathology, Box 3712, Duke University Medical Center, Durham, NC 27710, USA
    J Biol Chem 279:20993-8. 2004

Research Grants

  1. A LYMPHOBLAST MODEL FOR DISEASES OF METABOLISM
    Michael Hershfield; Fiscal Year: 1993
  2. LYMPHOBLAST MODEL FOR DISEASES OF PURINE METABOLISM
    Michael Hershfield; Fiscal Year: 2001
  3. A LYMPHOBLAST MODEL FOR DISEASES OF PURINE METABOLISM
    Michael Hershfield; Fiscal Year: 2006
  4. PEG-uricase as therapy for refractory gout
    Michael Hershfield; Fiscal Year: 2004
  5. A LYMPHOBLAST MODEL FOR DISEASES OF PURINE METABOLISM
    Michael Hershfield; Fiscal Year: 1990

Collaborators

Detail Information

Publications21

  1. pmc Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
    Nancy J Ganson
    Division of Rheumatology, Box 3049, Duke University Medical Center, Durham, NC 27710, USA
    Arthritis Res Ther 8:R12. 2006
    ..PEG immunogenicity deserves further investigation, because it has potential implications for other PEGylated therapeutic agents in clinical use...
  2. ncbi request reprint New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency
    Michael S Hershfield
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Eur J Immunol 35:25-30. 2005
    ..I also assess the relative contributions of Ado and dAdo to the pathogenesis of ADA-deficient SCID...
  3. pmc Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo
    Michael S Hershfield
    Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:14351-6. 2010
    ....
  4. ncbi request reprint Genotype is an important determinant of phenotype in adenosine deaminase deficiency
    Michael S Hershfield
    Box 3049, Rom 418 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Immunol 15:571-7. 2003
    ..A scale for ranking novel ADA alleles based on expression may have utility if newborn screening for primary immunodeficiency disorders is initiated...
  5. pmc Reassessing serum urate targets in the management of refractory gout: can you go too low?
    Michael S Hershfield
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Rheumatol 21:138-42. 2009
    ..Some hypothetical concerns with inducing hypouricemia are considered and relevant clinical evidence is evaluated...
  6. ncbi request reprint Uricase and other novel agents for the management of patients with treatment-failure gout
    John S Sundy
    Duke University Medical Center, Durham, NC 27710, USA
    Curr Rheumatol Rep 9:258-64. 2007
    ..In this article, we review the clinical characteristics associated with treatment-failure gout and discuss recent data from clinical trials of febuxostat and uricase...
  7. ncbi request reprint Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV
    Eva Richard
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biol Chem 277:19720-6. 2002
    ..1-1.3 kcal/mol. This cluster of 3 charged residues appears to be a "functional epitope" that accounts for about half of the difference between human and mouse ADA in free energy of binding to CD26...
  8. ncbi request reprint Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
    John S Sundy
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Arthritis Rheum 56:1021-8. 2007
    ..To evaluate the efficacy, immunogenicity, and tolerability of intravenous (IV) PEGylated recombinant mammalian urate oxidase (PEG-uricase) for the treatment of severe gout...
  9. ncbi request reprint Purine nucleoside phosphorylase deficiency (PNP-def) presenting with lymphopenia and developmental delay: successful correction with umbilical cord blood transplantation
    Laurie A Myers
    Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr 145:710-2. 2004
    ..This patient presented atypically with few infections and normal T-cell function. Progressive lymphopenia, ataxia, and developmental delay led to diagnosis. Umbilical cord blood transplantation corrected the immunodeficiency...
  10. ncbi request reprint Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells
    Mario Gonzalez-Gronow
    Department of Pathology, Box 3712, Duke University Medical Center, Durham, NC 27710, USA
    J Biol Chem 279:20993-8. 2004
    ..Thus, ADA may be a factor regulating events in prostate cancer cells that occur when Pg binds to the cell surface and is activated...
  11. ncbi request reprint Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy
    Francisco X Arredondo-Vega
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 99:1005-13. 2002
    ..During ADA replacement therapy, ADA activity in T cells and abundance of the "second-site" revertant allele decreased markedly. This finding raises an important issue relevant to stem cell gene therapy...
  12. ncbi request reprint E. coli expression system for identifying folding mutations of human adenosine deaminase
    Ines Santisteban
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Methods Mol Biol 232:175-82. 2003
  13. pmc Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report
    Barbara C Engel
    Division of Research Immunology Bone Marrow Transplantation, General Clinical Research Center, Department of Pathology, Children s Hospital Los Angeles, CA 90027, and Baylor College of Medicine, Houston, TX, USA
    Blood 109:503-6. 2007
    ..The confounding effects of this preexisting marrow cytogenetic abnormality on the response to gene transfer highlights another challenge of gene therapy with the use of autologous hematopoietic stem cells...
  14. ncbi request reprint A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency
    Bridget E Bax
    Child Health, Division of Clinical Developmental Sciences, St George s, University of London, London, UK
    Eur J Haematol 79:338-48. 2007
    ..Carrier erythrocyte-ADA therapy in an adult patient with ADA deficiency was shown to be metabolically and clinically effective...
  15. ncbi request reprint Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy
    Makoto Otsu
    Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 13:425-32. 2002
    ....
  16. doi request reprint An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complication
    Caner Aytekin
    Department of Pediatric Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey
    Pediatr Transplant 12:479-82. 2008
    ..This report presents a new PNP deficiency case successfully transplanted without a conditioning regimen from an HLA-identical family donor, who developed a complication of disseminated BCG infection...
  17. ncbi request reprint Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase
    David A Kaufman
    Department of Pediatrics, Louisiana State University Health Sciences Center, Shreveport, LA 71130 3239, USA
    Pediatrics 116:e876-9. 2005
    ..The possible mechanisms underlying such pathology are reviewed...
  18. ncbi request reprint The danger within
    Yiing Gu
    N Engl J Med 350:2721-2; author reply 2721-2. 2004
  19. ncbi request reprint Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications
    Manfred Hönig
    Department of Pediatrics, University of Ulm, University Clinic for Child and Adolescent Medicine, Eythstrasse 24, 89075 Ulm, Germany
    Blood 109:3595-602. 2007
    ..The high rate of neurologic abnormalities observed in long-term surviving patients with ADA deficiency indicates that HSCT commonly fails to control CNS complications in this metabolic disease...
  20. pmc polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency
    Elke Lainka
    Uniklinikum Essen, Kinderheilkunde, Hufelandstr 55, 45122 Essen, Germany
    Clin Diagn Lab Immunol 12:861-6. 2005
    ..In parallel, IL-2 secretion and the lymphocyte mitogenic response improved. Between 4 and 7 months, immunoglobulin G antibodies to bovine ADA developed and resulted in the complete reversal of immune recovery...
  21. ncbi request reprint Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID)
    Belinda Chan
    Division of Research Immunology B M T, Mailstop number 62, Childrens Hospital Los Angeles, University of Southern California Keck School of Medicine, 4650 Sunset Blvd, Los Angeles, CA 90027, USA
    Clin Immunol 117:133-43. 2005
    ..These patients should be followed closely to detect a premature decline in immune function with aging in future decades of PEG-ADA therapy...

Research Grants23

  1. A LYMPHOBLAST MODEL FOR DISEASES OF METABOLISM
    Michael Hershfield; Fiscal Year: 1993
    ....
  2. LYMPHOBLAST MODEL FOR DISEASES OF PURINE METABOLISM
    Michael Hershfield; Fiscal Year: 2001
    ..They will investigate the knockout mice as a model system to carry out biochemical studies that could not be done in human patients. ..
  3. A LYMPHOBLAST MODEL FOR DISEASES OF PURINE METABOLISM
    Michael Hershfield; Fiscal Year: 2006
    ..abstract_text> ..
  4. PEG-uricase as therapy for refractory gout
    Michael Hershfield; Fiscal Year: 2004
    ..Abstract Not Provided ..
  5. A LYMPHOBLAST MODEL FOR DISEASES OF PURINE METABOLISM
    Michael Hershfield; Fiscal Year: 1990
    ....